SV2A Antibody (E-8): sc-376234

SV2A Antibody (E-8) is a mouse monoclonal IgG1 kappa light chain antibody that detects SV2A protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). anti-SV2A antibody (E-8) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. SV2A protein, also known as Synaptic Vesicle 2A, plays a crucial role in synaptic transmission by regulating cytoplasmic calcium levels in presynaptic nerve terminals during repetitive stimulation, which is essential for maintaining normal brain function. SV2A protein is predominantly expressed in the subcortex and is found on all synaptic vesicles, regardless of the type of neurotransmitter, highlighting its importance in the overall process of neurotransmission. Additionally, SV2A is functionally redundant with SV2B, another isoform, ensuring that synaptic transmission remains efficient even if one isoform is compromised. The differential expression of SV2A and SV2B in the brain underscores their specific roles in various synaptic functions, making SV2A (E-8) monoclonal antibody a valuable tool for researchers studying synaptic mechanisms and neurobiology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SV2A Antibody (E-8) References:

1. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release.  |  Janz, R., et al. 1999. Neuron. 24: 1003-16. PMID: 10624962
2. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family.  |  Janz, R. and Südhof, TC. 1999. Neuroscience. 94: 1279-90. PMID: 10625067
3. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells.  |  Buckley, K. and Kelly, RB. 1985. J Cell Biol. 100: 1284-94. PMID: 2579958
4. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.  |  Ohno, Y. and Tokudome, K. 2017. CNS Neurol Disord Drug Targets. 16: 463-471. PMID: 28393712
5. Endocrine secretory granules and neuronal synaptic vesicles have three integral membrane proteins in common.  |  Lowe, AW., et al. 1988. J Cell Biol. 106: 51-9. PMID: 3276713
6. Imaging of Synaptic Density in Neurodegenerative Disorders.  |  Carson, RE., et al. 2022. J Nucl Med. 63: 60S-67S. PMID: 35649655
7. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.  |  Wu, PP., et al. 2024. Neurosci Bull. 40: 594-608. PMID: 37897555
8. Neuronal transcriptome, tau and synapse loss in Alzheimer's knock-in mice require prion protein.  |  Stoner, A., et al. 2023. Alzheimers Res Ther. 15: 201. PMID: 37968719
9. Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer's disease.  |  Wang, X., et al. 2024. Alzheimers Res Ther. 16: 82. PMID: 38615037
10. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.  |  Yamagata, A., et al. 2024. Nat Commun. 15: 3027. PMID: 38637505
11. SV2A PET imaging in human neurodegenerative diseases.  |  Bavarsad, MS. and Grinberg, LT. 2024. Front Aging Neurosci. 16: 1380561. PMID: 38699560
12. Brain contains two forms of synaptic vesicle protein 2.  |  Bajjalieh, SM., et al. 1993. Proc Natl Acad Sci U S A. 90: 2150-4. PMID: 7681585

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-SV2A Antibody (E-8) has 12 citations in a variety of scientific publications.

Primary antibodies like Anti-SV2A Antibody (E-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

SV2A Antibody (E-8) Specifications

Alternate Product Name: Synaptic Vesicle Glycoprotein 2A

Product Clone Name: E-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 2-25

Epitope Target: SV2A

Epitope Species: rat

Product Reactivity/Detection: SV2A

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 12 citations in various scientific publications

Available Conjugates/Forms for SV2A Antibody (E-8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin

The preferred SV2B antibody is SV2B Antibody (C-3): sc-166004.